Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September:

  • Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET
  • H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8 at 12:00 pm ET

A live webcast of the fireside chats can be accessed under “Events & Presentations” in the Investor section of the Company’s website, https://investor.verastem.com/events. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.73
+6.25 (2.89%)
AAPL  263.53
+1.29 (0.49%)
AMD  238.84
-1.72 (-0.71%)
BAC  51.69
-0.35 (-0.67%)
GOOG  252.42
-4.60 (-1.79%)
META  732.17
+0.00 (0.00%)
MSFT  516.42
-0.37 (-0.07%)
NVDA  181.28
-1.36 (-0.75%)
ORCL  275.32
-1.86 (-0.67%)
TSLA  445.75
-1.68 (-0.38%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.